Want to see HK:2138 full AI Analyst Report?
2138 Stock Chart & Stats
HK$0.57
-HK$0.01(-1.61%)
At close: 4:00 PM EST
HK$0.57
-HK$0.01(-1.61%)
Day’s Range― - ―
52-Week RangeHK$0.34 - HK$1.20
Previous CloseN/A
Volume263.00K
Average Volume (3M)629.78K
Market Cap
HK$503.71M
Enterprise ValueHK$1.22B
Total Cash (Recent Filing)HK$988.66M
Total Debt (Recent Filing)HK$1.26B
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.72%
Share Statistics
EPS (TTM)-0.34
Shares Outstanding1,185,211,300
10 Day Avg. Volume673,306
30 Day Avg. Volume629,783
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.14
P/FCF Ratio0.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)HK$5.02B
Bulls Say, Bears Say
Bulls Say
Positive Operating And Free Cash FlowConsistent positive operating and free cash flow (~606.6M in 2026) provides durable liquidity that supports day-to-day operations, servicing debt, and funding capex or strategic initiatives. This cash generation cushions the firm while accounting results are weak, reducing near-term refinancing risk.
Diversified Consumer-facing Healthcare ServicesA multi-vertical consumer healthcare model (health screening, medical aesthetics, primary/outpatient care) creates diversified revenue streams and internal referral potential. Structural demand for preventive and aesthetic services supports recurring packages and membership revenue, improving resilience versus single-segment peers.
Solid Underlying EBITDA MarginsA mid-teens EBITDA margin (~14.5%) indicates fundamentally profitable service economics before depreciation and below-the-line items. This margin profile supports cash generation and suggests the core business can be viable if non-cash charges or one-time items are addressed, aiding medium-term recovery prospects.
Bears Say
Multi-year Revenue Decline And Sustained LossesTwo consecutive years of revenue contraction and a swing to sustained net losses erode scale and operational leverage. Persistent top-line weakness strains margins, limits reinvestment capacity, and makes restoring profitable growth more difficult without clear demand or execution improvements.
Severe Gross Margin VolatilityA collapse in gross margin to ~15.9% from prior ~80%+ levels signals structural mix shifts, pricing pressure, or accounting reclassification. Such volatility undermines earnings quality and forecasting accuracy, increasing execution risk and reducing management's ability to plan long-term investments or margin restorations.
Weakening Balance Sheet And Rising LeverageRising debt-to-equity alongside declining equity and a deeply negative ROE (-29.1%) reduces financial flexibility and raises refinancing and interest-service risk. If profitability does not stabilize, higher leverage constrains strategic options and increases the chance of creditor-imposed restrictions or higher funding costs.
EC Healthcare News
2138 FAQ
What was EC Healthcare’s price range in the past 12 months?
EC Healthcare lowest stock price was HK$0.34 and its highest was HK$1.20 in the past 12 months.
What is EC Healthcare’s market cap?
EC Healthcare’s market cap is HK$503.71M.
When is EC Healthcare’s upcoming earnings report date?
EC Healthcare’s upcoming earnings report date is Nov 26, 2026 which is in 105 days.
How were EC Healthcare’s earnings last quarter?
EC Healthcare released its earnings results on Jun 29, 2026. The company reported -HK$0.331 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.331.
Is EC Healthcare overvalued?
According to Wall Street analysts EC Healthcare’s price is currently Overvalued.
Does EC Healthcare pay dividends?
EC Healthcare pays a Annually dividend of HK$0.01 which represents an annual dividend yield of 1.72%. See more information on EC Healthcare dividends here
What is EC Healthcare’s EPS estimate?
EC Healthcare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does EC Healthcare have?
EC Healthcare has 1,185,211,300 shares outstanding.
What happened to EC Healthcare’s price movement after its last earnings report?
EC Healthcare reported an EPS of -HK$0.331 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.219%.
Which hedge fund is a major shareholder of EC Healthcare?
Currently, no hedge funds are holding shares in HK:2138
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EC Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.48%
Trailing 12-Months
Company Description
EC Healthcare
EC Healthcare, an investment holding firm, delivers an extensive range of medical and healthcare services throughout Hong Kong, Macau, and mainland China. Its operations are structured into three primary divisions: Medical, Aesthetic Medical and Beauty and Wellness, and an 'Others' category. The company's diverse service offerings include quasi-medical treatments, beauty and wellness programs, medical imaging, surgical procedures, aesthetic medicine, dentistry, hair restoration, vaccinations, chiropractic care, psychological support, and orthopedic services. Beyond direct patient care, EC Healthcare also provides administrative and management support, laboratory diagnostics, various marketing and performance marketing solutions, and even travel agency services. Furthermore, it retails beauty and skincare products, manages healthcare machinery, engages in property investment, offers multi-channel networking, and extends its expertise to veterinary services. Its product and service portfolio is primarily marketed under proprietary brands such as PRODERMA LAB, Swissline, Suissebeaute, and re:HEALTH. Established in 2005 and headquartered in Mong Kok, Hong Kong, the company was formerly known as Union Medical Healthcare Limited before rebranding to EC Healthcare in April 2021.
Technical Analysis
Innovative Pharmaceutical Biotech
―
Natural Beauty Bio-Technology
―
Dingdang Health Technology Group Ltd.
―
Herbs Generation Group Holdings Limited Class H
―
Eternal Beauty Holdings Limited
―